Article by Innotéka magazine, an interview with Cantabio's CEO, Dr Gergely Tóth, describing the company's innovative approach to tacking the diseases by tackling the root causes of protein aggregation and oxidative stress.
Cantabio in the News
Cover Story by Biocentury Innovations, describing how Cantabio is using an alternative approach, enhancing the function of the DJ-1 protein, rather than the more common dopamine compensation strategy. This means developing a disease-modifying therapy instead of treating only the disease's symptoms. Mentioning also our pharmacological chaperone approach in Alzheimer's targeting B-amyloid and tau.
Interview with Dr. Gergely Tóth (founder and CEO), Dr. Thomas Sawyer (COO) regarding Cantabio's research and its preclinical development programs published in U.S. Pharma Newsletter.